Karduss Urueta A, Morales Polanco M R, Pizzuto Chávez J, Meillón García L A
Servicio de Hematología, Hospital de Especialidades CMN Siglo XXI, IMSS, México D.F.
Gac Med Mex. 1993 Jan-Feb;129(1):23-5.
The main objective of the present work is to describe the results of the treatment with ascorbic acid in thirteen patients with refractory chronic idiopathic thrombocytopenic purpura (CITP) and to compare its results with those informed in the literature. The patients received ascorbic acid 2 g/day, orally, in the morning during at least eight weeks. At the end of the period of control there were only four partial responses (30%); the remaining patients did not experience any kind of favorable reaction. Previous publications informed mean partial and complete responses of 11 and 19% respectively. According to such results and those of the present work, and taking into account the generally transitory duration of the response it is concluded that ascorbic acid is of no use in the treatment of CITP.
本研究的主要目的是描述13例难治性慢性特发性血小板减少性紫癜（CITP）患者接受抗坏血酸治疗的结果，并将其结果与文献中报道的结果进行比较。患者每天口服2克抗坏血酸，于早晨服用，至少持续8周。在对照期结束时，仅有4例部分缓解（30%）；其余患者未出现任何有利反应。先前的出版物报道的平均部分缓解率和完全缓解率分别为11%和19%。根据这些结果以及本研究的结果，并考虑到反应通常持续时间短暂，得出结论：抗坏血酸对CITP治疗无效。
